Early Access — free while we kick the tires
EdgarHawk

Grossman Adam S

President and CEO

Director Officer
3 filings analyzed · 1 company · Latest 2024-11-22

Companies

Company Buys Sells Direction
ADMA BIOLOGICS, INC. ADMA 0 13 Net selling

Activity

November 2024
2024-11-22 ADMA BIOLOGICS, INC. ADMA
medium
Sell
48,967 shares
$1,033,204
Significance 5/10

ADMA CEO Grossman sold 48,967 shares at $21.10 on 2024-11-22 (pre-transaction: 2,037,974 shares, post: 1,989,007). Stock near 52-week high ($22.62); up 35.0% in 30 days.

CEO Adam Grossman sold 48,967 shares worth $1,033,203.70, reducing his holdings by 2.4% at $21.10, just 0.08 below the current price of $21.18 and near the 52-week high of $22.62. The stock has appreciated 35.0% over 30 days and 15.1% over 90 days, while the company reports strong recent fundamentals with $119.8M quarterly revenue and $35.9M net income. His cross-ticker track record shows a 75.00% well-timed sell rate with a 6.7% average 90-day return, though at ADMA specifically, timing outcomes have been mixed—two of three prior measurable sales occurred before stock declines, but the two most recent sells in August showed positive 30-day returns of 10.2% and 12.4%. The sale appears executed near technical strength rather than anticipation of deterioration.

August 2024
2024-08-27 ADMA BIOLOGICS, INC. ADMA
high
Sell
626,245 shares
$10,923,987
Significance 7/10

CEO Grossman sells 626,245 shares (23.3% of holdings) for $10.9M at $17.44 avg; stock near 52-wk high.

Adam S Grossman, President and CEO, executed 2 separate sales on 2024-08-26 and 2024-08-27 totaling 626,245 shares for $10,923,987.26 ($10.9M), reducing his holdings from 2,685,971 to 2,059,726 shares (-23.3%). The blended average sale price of $17.44 is close to the current price of $17.35 and within 5.7% of the 52-week high of $18.40. His prior 4 open-market sells across all tickers show a 100% well-timed rate at the 90-day mark with an average 90-day return of -12.6%, and at ADMA specifically, 3 of 3 prior measurable sells (2023-08-15, 2023-08-16, 2023-08-18) were well-timed with 90-day returns of -17.7%, -11.7%, and -8.3% respectively. However, the June 2024 sale at ADMA showed a 30-day return of +19.2%, and current 30-day and 90-day performance is +31.8% and +84.6%, indicating substantial recent appreciation. The company reported quarterly revenue of $107,191,000 and net income of $32,062,000 with annual revenue growth of +67.6%, though full-year net income was negative despite the recent profitable quarter.

June 2024
2024-06-14 ADMA BIOLOGICS, INC. ADMA
medium
Sell
100,000 shares
$1,071,980
Significance 6/10

CEO/President Adam Grossman sells 100,000 shares of ADMA at $10.72 amid 77.5% 90-day surge

Grossman sold 100,000 shares (100.0K shares) at $10.72 on 2024-06-14, reducing his holdings by 100,000 shares (-4.6% vs pre-transaction holdings) while the stock was at -1.4% from its 52-week high of $10.78. The stock had surged 77.5% over the prior 90 days and 16.8% over the prior 30 days before this sale. Grossman's prior three sales at ADMA occurred in August 2023, all generating negative 90-day returns (-8.3%, -11.7%, -17.7%), establishing a 3-of-3 pattern of well-timed sales at the 90-day mark at this ticker. His cross-ticker track record shows 3 prior sells with a 100.00% 90-day well-timed rate and average 90-day return of -12.6%, indicating a consistent pattern of selling before subsequent declines. The company reported strong recent fundamentals—$81,875,000.00 in quarterly revenue, $17,806,000.00 net income in the latest quarter, and 67.6% annual revenue growth—yet was unprofitable over its most recent full fiscal year, creating ambiguity between near-term momentum and structural profitability.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access